Therapeutic Area: Oncology
Safety and Clinical Activity of Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer: a Phase I Study
Petrylak DP., et al.
Clinical Cancer Research
February 2021
Authors and Affiliates
Daniel P Petrylak 1, Yohann Loriot 2, David Shaffer 3, Fadi Braiteh 4, John Powderly 5, Lauren C Harshman 6, Paul Conkling 7, Jean-Pierre Delord 8, Michael Gordon 9, Joseph W Kim 10, Indrani Sarkar 11, Kobe C Yuen 12, Edward E Kadel 13, Sanjeev Mariathasan 14, Carol O'Hear 11, Sujata Narayanan 11, Marcella Fassò 15, Susheela Carroll 16, Thomas Powles 17;
1 Prostate and Urologic Cancers Program, Yale Cancer Center daniel.petrylak@yale.edu.
2 Vancouver Prostate Centre, Gustave Roussy, INSERM U981.
3 Medicine, New York Oncology Hematology.
4 Translational Oncology Program, Comprehensive Cancer Centers of Nevada.
5 Oncology, Carolina BioOncology Institute.
6 Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute.
7 Virginia Oncology Associates, US Oncology Phase I Group.
8 Clinical Research Unit, Institut Claudius Regaud, IUCT-Oncopole.
9 HonorHealth Research Institute.
10 Department of Medicine, Yale University.
11 Genentech, Inc.
12 Oncology Biomarker Development, Genentech.
13 Oncology Biomarker Development, Genentech, Inc.
14 Genentech.
15 PDO, Genentech, Inc.
16 Clinical Science, Genentech, Inc.
17 Experimental Cancer Medicine Centre, Queen Mary University of London.
αβγδ T cells play a vital role in fetal human skin development and immunity
Reitermaier R., et al.
Journal of Experimental Medicine
February 2021
Authors and Affiliates
René Reitermaier 1, Thomas Krausgruber 2, Nikolaus Fortelny 2, Tanya Ayub 1, Pablo Augusto Vieyra-Garcia 3, Philip Kienzl 1, Peter Wolf 3, Anke Scharrer 4, Christian Fiala 5,6, Marita Kölz 4, Manuela Hiess 7, Martin Vierhapper 8, Christopher Schuster 1, Andreas Spittler 9, Christof Worda 10, Wolfgang Weninger 1, Christoph Bock 2,11, Wolfgang Eppel 10, Adelheid Elbe-Bürger 1;
1 Department of Dermatology, Medical University of Vienna, Vienna, Austria.
2 Research Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, Vienna, Austria.
3 Department of Dermatology, Medical University of Graz, Graz, Austria.
4 Department of Pathology, Medical University of Vienna, Vienna, Austria.
5 Gynmed Clinic, Vienna, Austria.
6 Department of Women's and Children's Health, Division of Obstetrics and Gynaecology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.
7 Department of Urology, Medical University of Vienna, Vienna, Austria.
8 Department of Surgery, Division of Plastic and Reconstructive Surgery, Medical University of Vienna, Vienna, Austria.
9 Core Facilities, Flow Cytometry, Medical University of Vienna, Vienna, Austria.
10 Department of Obstetrics & Gynecology, Medical University of Vienna, Vienna, Austria.
11 Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Safety, anti-tumor activity and T-cell responses in a dose-ranging phase 1 trial of the oncolytic peptide LTX-315 in patients with solid tumors
Spicer J., et al.
Clinical Cancer Research
February 2021
Authors and Affiliates
James Spicer 1, Aurelien Marabelle 2, Jean-Francois Baurain 3, Nina Louise Jebsen 4, Dag Eirik Jøssang 5, Ahmad Awada 6, Rebecca Kristeleit 7, Delphine Loirat 8, George Lazaridis 9, Christiane Jungels 10, Paal Brunsvig 11, Berit Nicolaisen 12, Andrew Saunders 13, Hamina Patel 13, Jerome Galon 14, Fabienne Hermitte 15, Ketil André Camilio 13, Brynjar Mauseth 13, Vibeke Sundvold 16, Baldur Sveinbjørnsson 17, Øystein Rekdal 13;
1 School Cancer & Pharmacological Sciences, King's College London james.spicer@kcl.ac.uk.
2 Institut Gustave Roussy.
3 King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc.
4 Centre for Cancer Biomarkers, Dep. of Clinical Science and Dep. of Oncology, University of Bergen and Haukeland University Hospital, Bergen.
5 Haukeland University Hospital.
6 Oncology Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles.
7 Dept of Oncology, Guy's and St Thomas' NHS Foundation Trust.
8 Medical Oncology, Institute Curie.
9 Guy's Hospital, King's College London.
10 Department of Medical Oncology, Institut Jules Bordet.
11 Oslo University Hospital.
12 Medical, Lytix Biopharma AS.
13 Lytix Biopharma AS.
14 Inserm U1138, Laboratory of Integrative Cancer Immunology.
15 Medical Affairs, HalioDx, Marseille, France.
16 Biopharma, Lytix Biopharma (Norway).
17 Cell Biology and Histology, University of Norway.
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Nowicki NS., et a.
Clinical Cancer Research
February 2021
Authors and Affiliates
Theodore S Nowicki 1, Beata Berent-Maoz 2, Gardenia Cheung-Lau 2, Rong Rong Huang 3, Xiaoyan Wang 4, Jennifer Tsoi 2, Paula Kaplan-Lefko 2, Paula Cabrera 2, Justin Tran 2, Jia Pang 2, Mignonette Macabali 2, Ivan Perez Garcilazo 2, Ignacio Baselga Carretero 2, Anusha Kalbasi 5,6,7, Alistair J Cochran 3, Catherine S Grasso 2, Siwen Hu-Lieskovan 2, Bartosz Chmielowski 2, Begoña Comin-Anduix 6,7, Arun Singh 8, Antoni Ribas 8,6,7,9,10;
1 Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California.
2 Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
3 Department of Pathology, University of California Los Angeles, Los Angeles, California.
4 Department of General Internal Medicine and Health Services Research, University of California Los Angeles, Los Angeles, California.
5 Division of Molecular and Cellular Oncology, Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California.
6 Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.
7 Division of Surgical-Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California.
8 Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California. asingh@mednet.ucla.edu aribas@mednet.ucla.edu.
9 Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, California.
10 Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients
Authors and Affiliates
Leila Amini 1, Dimitrios Laurin Wagner 2, Uta Rössler 3, Ghazaleh Zarrinrad 4, Livia Felicitas Wagner 5, Tino Vollmer 6, Désirée Jacqueline Wendering 7, Uwe Kornak 3, Hans-Dieter Volk 1, Petra Reinke 2, Michael Schmueck-Henneresse 8;
1 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany.
2 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany.
3 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Institute of Medical Genetics and Human Genetics, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany.
4 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Einstein Center for Regenerative Therapies, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany.
5 Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany.
6 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany.
7 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany.
8 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. Electronic address: michael.schmueck-henneresse@charite.de.
Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors
Crosby EJ., et al.
OncoImmunology
February 2021
Authors and Affiliates
Erika J Crosby 1, Junping Wei 1, Xiao Yi Yang 1, Gangjun Lei 1, Tao Wang 1, Cong-Xiao Liu 1, Pankaj Agarwal 1, Alan J Korman 2, Michael A Morse 1,3, Kenneth Gouin 4, Simon R V Knott 4, H Kim Lyerly 1,5, Zachary C Hartman 1;
1 Department of Surgery, Duke University, Durham, NC, United States.
2 Immuno-Oncology Discovery, Bristol-Myers Squibb Company, Redwood City, CA, United States.
3 Department of Medicine, Duke University, Durham, NC, United States.
4 Department of Biomedical Sciences, Cedars-Sinai Medical Institute, Los Angeles, CA, United States.
5 Department of Pathology/Immunology, Duke University, Durham, NC, United States
Characterization of ascites- and tumor-infiltrating γδ T cells reveals distinct repertoires and a beneficial role in ovarian cancer
Authors and Affiliates
Emelie Foord 1, Lucas C M Arruda 2, Ahmed Gaballa 2,3, Charlotte Klynning 4, Michael Uhlin 2,5,6;
1 Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 171 77 Stockholm, Sweden. emelie.foord@ki.se.
2 Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 171 77 Stockholm, Sweden.
3 Department of Clinical Biochemistry, National Liver Institute, Menoufia University, 511 32 Shebin Elkom, Egypt.
4 Department of Gynecological Oncology, Karolinska University Hospital, 171 76 Stockholm, Sweden.
5 Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, 141 86 Stockholm, Sweden.
6 Department of Applied Physics, Royal Institute of Technology, 100 44 Stockholm, Sweden.
Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups
Authors and Affiliates
Sanghoon Lee 1, Li Zhao 2, Latasha D. Little 2, Shannon N. Westin 3, Amir A. Jazarei 3, Nicole D. Fleming 3, Jianhua Zhang 2, P. Andrew Futreal 2, Anil K. Sood 3;
1 Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3 Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
Yu J., et al.
Nature Medicine
January 2021
Authors and Affiliates
Jiali Yu 1,2, Michael D Green 3,4,5, Shasha Li 1,2,6, Yilun Sun 7,8, Sara N Journey 9, Jae Eun Choi 10,11, Syed Monem Rizvi 12, Angel Qin 13, Jessica J Waninger 9,11, Xueting Lang 1,2, Zoey Chopra 9, Issam El Naqa 7,14, Jiajia Zhou 1,2, Yingjie Bian 1,2, Long Jiang 2,7, Alangoya Tezel 9, Jeremy Skvarce 9, Rohan K Achar 9,15, Merna Sitto 7, Benjamin S Rosen 7, Fengyun Su 10,11, Sathiya P Narayanan 10,11, Xuhong Cao 10,11,16, Shuang Wei 1,2, Wojciech Szeliga 1,2, Linda Vatan 1,2, Charles Mayo 7, Meredith A Morgan 7, Caitlin A Schonewolf 7, Kyle Cuneo 7, Ilona Kryczek 1,2, Vincent T Ma 13, Christopher D Lao 13, Theodore S Lawrence 7, Nithya Ramnath 17,13, Fei Wen 12, Arul M Chinnaiyan 10,11,16, Marcin Cieslik 6,10,11, Ajjai Alva 2,13, Weiping Zou 18,19,20,21,22;
1 Department of Surgery, University of Michigan, Ann Arbor, MI, USA.
2 Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
3 Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA. migr@med.umich.edu.
4 Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA. migr@med.umich.edu.
5 Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI, USA. migr@med.umich.edu.
6 Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
7 Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
8 Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
9 University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA.
10 Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
11 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
12 Chemical Engineering, University of Michigan, Ann Arbor, MI, USA.
13 Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
14 Machine Learning Department, Moffitt Cancer Center, Tampa, FL, USA.
15 University of Michigan School of Public Health, Ann Arbor, MI, USA.
16 Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA.
17 Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI, USA.
18 Department of Surgery, University of Michigan, Ann Arbor, MI, USA. wzou@med.umich.edu.
19 Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA. wzou@med.umich.edu.
20 Department of Pathology, University of Michigan, Ann Arbor, MI, USA. wzou@med.umich.edu.
21 Graduate Program in Immunology, University of Michigan Medical School, Ann Arbor, MI, USA. wzou@med.umich.edu.
22 Graduate Program in Cancer Biology, University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA. wzou@med.umich.edu.